Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells

@inproceedings{Li2015TreatmentWA,
  title={Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells},
  author={Luyuan Li and Ana Cristina Paz and Breelyn A. Wilky and Britt K Johnson and Karina A. Galoian and Andrew Rosenberg and Guozhi Hu and Gabriel Tinoco and Olaf A F Bodamer and Jonathan C. Trent and Ken Mills},
  booktitle={PloS one},
  year={2015}
}
Chondrosarcomas are malignant bone tumors that produce cartilaginous matrix. Mutations in isocitrate dehydrogenase enzymes (IDH1/2) were recently described in several cancers including chondrosarcomas. The IDH1 inhibitor AGI-5198 abrogates the ability of mutant IDH1 to produce the oncometabolite D-2 hydroxyglutarate (D-2HG) in gliomas. We sought to determine if treatment with AGI-5198 would similarly inhibit tumorigenic activity and D-2HG production in IDH1-mutant human chondrosarcoma cells… CONTINUE READING